Cetuximab

西妥昔单抗

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameCetuximab
Drug Alias NameCetuximabumAnti-EGFR monoclonal antibody 225爱必妥ErbituxIMC-C255 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Solid tumoursNeuralgia +[51] 
Global Approved IndicationsHead and Neck NeoplasmsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2004/02/12
Country/TerritoryCzechiaBelgiumCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck SeronoBristol-Myers Squibb CompanyEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesMerck Serono Co LtdImclone GmbhUniversity Medical Center Groningen +[16] 
Inactive CompaniesShenzhen Hank Bioengineering InstituteUtah State UniversityHeinrich Heine University Dusseldorf +[26] 
Active IndicationsOropharyngeal NeoplasmsHypopharyngeal NeoplasmsLaryngeal Neoplasms +[13] 
Inactive IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Solid tumoursNeuralgia +[38] 

Other Information

ATC CodeL01XC06
Related LinksWikipediaDrugBankKEGG